24-methylene cycloartenol | 1449-09-8

• 物质功能分类: 天然产物 - 萜类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 24-methylene cycloartenol
• 英文别名: 24-Methylenecycloartanol；24-Methylene-cycloartanol；(1S,3R,6S,8R,12S,15R,16R)-7,7,12,16-tetramethyl-15-[(2R)-6-methyl-5-methylideneheptan-2-yl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-6-ol
• CAS: 1449-09-8；13614-08-9；118628-12-9
• 化学式: C₃₁H₅₂O
• 分子量: 440.753
• InChiKey: BDHQMRXFDYJGII-PDJDWEBQSA-N

物化性质

• 熔点：
  121-122 °C
• 沸点：
  512.7±19.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.3
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them
  申请人：AMANO PHARMACEUTICAL CO., LTD.

  公开号：EP0166542A2

  公开（公告）日：1986-01-02

  A triterpenyl ester of organic acid other than triterpenyl esters of ferulic acid and of monobasic and dibasic saturated fatty acids. A process for producing a triterpenyl ester of organic acid other than esters of ferulic acid and of monobasic and dibasic saturated fatty acids, which comprises the reaction of a triterpenyl alcohol with an acid halide of the corresponding organic acid. A pharmaceutical composition for treatment of hyperlipidemia comprising a pharmaceutical carrier and an effective amount of a triterpenyl ester of organic acid other than triterpenyl esters of dibasic saturated fatty acids. A pharmaceutical composition for treating hyperlipidemia which comprises a pharmaceutical carrier and an effective amount of cyclobranol as an active ingredient.

  一种除阿魏酸三萜酯和单盐基及二盐基饱和脂肪酸三萜酯以外的有机酸三萜酯。一种除阿魏酸酯、单基和二基饱和脂肪酸酯以外的有机酸三萜酯的生产工艺，包括三萜醇与相应有机酸的酸卤化物反应。一种治疗高脂血症的药物组合物，包括药物载体和有效量的有机酸三萜酯（二元饱和脂肪酸三萜酯除外）。一种治疗高脂血症的药物组合物，它包括一种药物载体和有效量的作为活性成 分的环烷醇。
• PROCESS FOR PRODUCTION OF TRITERPENE ALCOHOL
  申请人：Kao Corporation

  公开号：EP2607372A1

  公开（公告）日：2013-06-26

  A process for producing triterpene alcohol, comprising sequentially conducting the following steps (A) to (C): (A) subjecting γ-oryzanol to alkaline hydrolysis; (B) mixing the alkaline hydrolysate with a low polarity organic solvent, and extracting triterpene alcohol to obtain a triterpene alcohol-containing low polarity organic solvent; and (C) adding water to the triterpene alcohol-containing low polarity organic solvent thus obtained, removing the low polarity organic solvent, and then melting triterpene alcohol in hot water, followed by cooling.

  一种生产三萜醇的工艺，包括依次进行以下步骤(A)至(C)： (A) 对γ-oryzanol 进行碱性水解； (B) 将碱性水解物与低极性有机溶剂混合，提取三萜醇，得到含三萜醇的低极性有机溶剂；以及 (C) 将水加入由此获得的含三萜醇的低极性有机溶剂中，除去低极性有机溶剂，然后在热水中熔化三萜醇，冷却。
• CYCLOARTENOL-CONTAINING COMPOSITION
  申请人：Kao Corporation

  公开号：EP3120854A1

  公开（公告）日：2017-01-25

  Provided is a cycloartenol-containing composition which can be used as a material for food and beverage, cosmetics, or the like, and has high biological activities. The cycloartenol-containing composition has a cycloartenol content of more than 37% by mass, a 24-methylenecycloartanol content of more than 5% by mass, and a sum content of cycloartenol and 24-methylenecycloartanol of more than 76% by mass, relative to the total mass of sterols.

  本发明提供了一种含环木菠萝烯醇的组合物，该组合物可用作食品和饮料、化妆品或类似产品的材料，并具有很高的生物活性。这种含环木菠萝烯醇的组合物中环木菠萝烯醇的含量大于 37%（按质量计），24-亚甲基环木菠萝烯醇的含量大于 5%（按质量计），环木菠萝烯醇和 24-亚甲基环木菠萝烯醇的总含量大于甾醇总质量的 76%（按质量计）。
• Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration
  申请人：——

  公开号：US20040067910A1

  公开（公告）日：2004-04-08

  The invention concerns a pharmaceutical or cosmetic composition, characterised in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a pharmaceutically or cosmetically acceptable carrier. Said composition enables to inhibit considerably Langerhans' cell migration induced by the presence or an allergenic agent.

  本发明涉及一种药物或化妆品组合物，其特征在于它至少包含一种用于抑制朗格汉斯细胞迁移的化合物，所述活性化合物选自蛋白激酶 C (PKC) 抑制化合物、基质金属蛋白酶 (MMP) 抑制化合物及其组合，以及至少一种药学上或化妆品上可接受的载体。所述组合物能够显著抑制由过敏原或过敏原制剂诱导的朗格汉斯细胞迁移。
• PROCEDE DE PREPARATION D'UN ESTER DE CORPS GRAS ET SON UTILISATION DANS LES DOMAINES PHARMACEUTIQUE, COSMETIQUE OU ALIMENTAIRE
  申请人：Laboratoires Expanscience

  公开号：EP1301460B1

  公开（公告）日：2008-08-06